Search

Historical outcomes remain poor for patients with relapsed/refractory diffuse large B-cell (DLBCL) and high-grade B-cell lymphoma (HGBCL) (Crump I et al i ., [3]). We included patients treated from 2011 to 2018, including those with transformed disease, patients with I MYC i , I BCL2 i and I BCL6 i translocations (including HGBCL), and patients treated with concurrent rituximab. Though more patients with transformed FL were treated with concurrent rituximab compared to patients with I de novo i GCB disease, there was no difference in efficacy between patients treated with or without concurrent rituximab. One patient with "triple HIT" disease had a complete response, which allowed the patient to receive chimeric antigen receptor T-cell therapy. [Extracted from the article]